The National MS Society’s annual continuing medical education conference will be held at the Bell Harbor Conference Center in Seattle, WA, Saturday, June 9. This is the premiere MS-focused conference in the region, attracting an audience of neurologists, physiatrists, nurse practitioners, physician assistants, and others involved in the search for answers to the complex questions of multiple sclerosis.
Thank you for attending the WSNS 2018 Annual Meeting. Please take a few minutes to complete our meeting evaluation. Your feedback helps us to create a meeting that will help you and your practice succeed!
If you have any questions, please email Becky Constantine at firstname.lastname@example.org
Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome. ClinicalTrials.gov Identifier: NCT02834793
• Participants must have a diagnosis of Lennox-Gastaut Syndrome (LGS) as evidenced by:
• more than one type of generalized seizure, including drop seizures (atonic, tonic, or myoclonic) for at least 6 months before Visit 1;
• an EEG reporting diagnostic criteria for LGS at some point in their history (abnormal background activity accompanied by slow, spike, and wave pattern <2.5 Hz).
• At least 2 years old at the time of consent.
• Have been <11 years old at the onset of LGS.
• At least 2 drop seizures per week in the 4-week Baseline Period preceding randomization.
• Receiving 1 to 3 concomitant AEDs at a stable dose for at least 30 days before Visit 1 (vagal nerve stimulation (VNS) and ketogenic diet do not count as AEDs).
• Presence of progressive neurological disease
• Presence of drop seizure clusters where individual seizures cannot be reliably counted (seizure clusters are defined as ≥2 drop seizures with <5 minutes between any 2 consecutive seizures)
• Prior treatment with perampanel with discontinuation due to safety issues (related to perampanel)
• Prior treatment with perampanel must have been discontinued at least 30 days before Visit 1
• Evidence of clinically significant disease (eg, cardiac, respiratory, gastrointestinal, renal disease, hepatic disease) that in the opinion of the investigator(s) could affect the participant’s safety or study conduct
• Scheduled for epilepsy-related surgery or any other form of surgery during the projected course of the study
• Ketogenic diet and VNS, unless stable and ongoing, for at least 30 days before Visit 1
David Vossler, MD and Carole Burton RN, Rainier Clinical Research Center, Inc.
Renton, Washington, United States, 98057. Phone 1 425-251-1720